Cipla Limited — Aspirin Exporter Profile
Indian Pharmaceutical Exporter · #2 for Aspirin · $2.5M export value · DGFT Verified
Cipla Limited is the #2 Indian exporter of Aspirin with $2.5M in export value and 240 verified shipments. Cipla Limited holds a 6.5% market share in Aspirin exports across 2 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Aspirin Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Aspirin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NEW ZEALAND | $1.9M | 122 | 76.7% |
| AUSTRALIA | $573.0K | 118 | 23.3% |
Cipla Limited exports Aspirin to 2 countries. The largest destination is NEW ZEALAND accounting for 76.7% of Cipla Limited's Aspirin shipments. These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Aspirin from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| HELLMANN WORLDWIDE LOGISTICS | NEW ZEALAND | $1.9M | 122 |
| APOTEX AUSTRALIA | AUSTRALIA | $175.5K | 20 |
| ARROW PHARMACEUTICALS PTY LTD, | AUSTRALIA | $135.0K | 27 |
| ARROW PHARMACEUTICALS PTY LTD | AUSTRALIA | $84.7K | 17 |
| NOUMED PHARMACEUTICALS PTY LIMITED | AUSTRALIA | $65.0K | 19 |
| NOUMED PHARMACEUTICALS PTY LTD | AUSTRALIA | $59.0K | 20 |
| ARROW PHARMACEUTICALS PTY LTD.., | AUSTRALIA | $36.6K | 12 |
| ARROW PHARMACEUTICALS PTY LIMITED | AUSTRALIA | $17.3K | 3 |
Cipla Limited supplies Aspirin to 8 buyers globally. The largest buyer is HELLMANN WORLDWIDE LOGISTICS (NEW ZEALAND), followed by APOTEX AUSTRALIA (AUSTRALIA) and ARROW PHARMACEUTICALS PTY LTD, (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Aspirin Export Value and How Much Does Cipla Limited Contribute?
India exported $23.7M worth of Aspirin through 3,422 shipments from 327 suppliers to 121 countries, serving 805 buyers globally. Cipla Limited contributes $2.5M to this total, accounting for 6.5% of India's Aspirin exports. Cipla Limited ships Aspirin to 2 countries through 8 buyers.
What Is the Average Shipment Value for Cipla Limited's Aspirin Exports?
Cipla Limited's average Aspirin shipment value is $10.3K per consignment, based on 240 shipments totaling $2.5M. The largest destination is NEW ZEALAND (76.7% of Cipla Limited's Aspirin exports).
How Does Cipla Limited Compare to Other Indian Aspirin Exporters?
Cipla Limited ranks #2 among 327 Indian Aspirin exporters with a 6.5% market share. The top 3 exporters are RECKITT BENCKISER (INDIA) PRIVATE LIMITED ($3.8M), CIPLA LIMITED ($2.5M), RECKITT BENCKISER INDIA PRIVATE LIMITED ($2.2M). Cipla Limited processed 240 shipments to 2 destination countries.
What Aspirin Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ETHICS ASPIRIN ENTERIC COATED 100 MG TAB | $505.5K | 18 |
| ETHICS ASPIRIN ENTERIC COATED 100MG TABL | $140.7K | 6 |
| APOHEALTH ASPIRIN SOLUBLE 300 MG TABLET | $89.3K | 9 |
| CHEMISTS' OWN LOW DOSE ASPIRIN 100 MG ENTERIC COATED TABLETENTERICCOATED ASPIRIN TABLETS BP 100 MG INV QT | $36.6K | 12 |
| ETHICS DISPERSIBLE ASPIRIN TABLETS 300MG | $34.6K | 5 |
| TERRYWHITE CHEMMART LOW DOSE ASPIRIN 100 | $28.8K | 7 |
| ETHICS ASPIRIN ENTERIC COATED 100 MG TABLET (ACETYL SALICYLIC ACID 100 MG)- -CI02058 ( INV.QTY. 4080 PACK 33 | $24.0K | 1 |
| ETHICS ASPIRIN ENTERIC COATED 100 MG TABLET (ACETYL SALICYLIC ACID 100 MG)- -CI02058 ( INV.QTY. 4061 PACK 33 | $23.9K | 1 |
| ETHICS ASPIRIN ENTERIC COATED 100MG TABLET (ACETYL SALICYLIC ACID 100 MG)- CI02058 INV.QTY.4083 PACK 33X30'S= | $23.8K | 3 |
| ETHICS ASPIRIN ENTERIC COATED 100 MG TABLET (ACETYL SALICYLIC ACID 100 MG)- CI02058 (INV.QTY 4062 PACK 33X30S=4021380 N | $23.8K | 1 |
Cipla Limited exports 141 distinct Aspirin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ETHICS ASPIRIN ENTERIC COATED 100 MG TAB with 18 shipments worth $505.5K.
Regulatory Requirements: Exporting Aspirin to Key Markets
What Cipla Limited must comply with to export Aspirin to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Aspirin Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | RECKITT BENCKISER (INDIA) PRIVATE LIMITED | $3.8M | 268 | 2 | $14.0K |
| 2 | CIPLA LIMITED ★ | $2.5M | 240 | 2 | $10.3K |
| 3 | RECKITT BENCKISER INDIA PRIVATE LIMITED | $2.2M | 86 | 1 | $25.6K |
| 4 | ADCOCK INGRAM LIMITED | $1.9M | 138 | 1 | $14.0K |
Cipla Limited ranks #2 among 327 Indian Aspirin exporters. Average shipment value of $10.3K compared to the market average of $72.4K. The closest competitors by value are RECKITT BENCKISER (INDIA) PRIVATE LIMITED and RECKITT BENCKISER INDIA PRIVATE LIMITED.
Which Indian Ports Ship Aspirin Exports?
| Port | Shipments | % Share |
|---|---|---|
| BANGALORE ICD | 426 | 12.4% |
| SAHAR AIR | 424 | 12.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 373 | 10.9% |
| NHAVA SHEVA SEA (INNSA1) | 348 | 10.2% |
| JNPT/ NHAVA SHEVA SEA | 159 | 4.6% |
| JNPT | 124 | 3.6% |
| Bombay Air | 107 | 3.1% |
| BANGALORE ICD (INWFD6) | 104 | 3.0% |
Geopolitical & Trade Policy Impact on Cipla Limited's Aspirin Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Aspirin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Aspirin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Aspirin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 240 individual customs records matching Cipla Limited exporting Aspirin, covering 141 formulations to 2 countries via 8 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 121+ countries, 805+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Aspirin Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Aspirin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Aspirin Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Aspirin. For current shipment-level data, contact TransData Nexus.